when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
calendar
approval

approval

DUPIXENT (DUPILUMAB) — FDA approval

October 19, 2018$REGN dupilumabupdated 5mo ago

community read0 votes

Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

view source ↗

Data sources

last refreshed 5mo ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

drug timeline · 8

phase 2 completionBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)Apr 30, 2026 · 160d ago
pdufaRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)Apr 27, 2026 · 163d ago
approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2026 · 174d ago
approvalDUPIXENT (DUPILUMAB) — FDA approvalFeb 23, 2026 · 226d ago
approvalDUPIXENT (DUPILUMAB) — FDA approvalJun 18, 2025 · 476d ago
approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 17, 2025 · 538d ago
approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2025 · 539d ago
approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 27, 2024 · 740d ago

same company · ±60 days · 3

approvalalirocumab: PRALUENT (ALIROCUMAB) — FDA approvalNov 6, 2018
approvalcemiplimab: LIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalSep 28, 2018
approvalalirocumab: PRALUENT (ALIROCUMAB) — FDA approvalAug 22, 2018

🐶 often sniffed alongside

top 7

drugDUPIXENT126 co-mentions · 33 sources
tagApproval124 co-mentions · 31 sources
companyBrigham and Women's Hospital1 co-mentions · 1 sources
tagPulmonology1 co-mentions · 1 sources
tagDermatology1 co-mentions · 1 sources
tagAsthma1 co-mentions · 1 sources
tagPDUFA1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?